• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
SLM Corporation - Common Stock
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:RTGN)

3.990 UNCHANGED
Last Price Updated: 3:45 PM EDT, Sep 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.990
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 3.990
Today's Range 3.990 - 3.990
52wk Range 3.200 - 4.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study
January 14, 2026
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
October 16, 2025
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire

Performance

52-Week Range 0.2% below 52-week high
3.990
3.2052W Low 4.0052W High

(RTGN) traded between $3.20 and $4.00 over the past 52 weeks and last traded at $3.99, 0.2% below its 52-week high.

Past 12 Months
N/A
N/A
N/A
-0.2%
-0.2%
+1.9%
1W  
1M  
3M  
6M -$0.01
YTD -$0.01
1Y +$0.08

RTGN was +1.9% over the past year, -0.2% over six months, -0.2% year to date.

12 Months vs Market
RTGN
+1.9%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months RTGN returned +1.9% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity
6M
12.0
YTD
12.0
1Y
2.3K

More News

Read More
News headline image
RetinalGenix Technologies and RGEN Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
October 01, 2025
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care
September 25, 2025
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening
June 27, 2025
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs
May 05, 2025
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGenix Technologies Welcomes Dr. Taimour Langaee as Advisor for DNA GPS Pharmacogenetics Initiatives
June 13, 2025
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGenix Technologies to Participate at the 37th Annual Roth Conference
March 06, 2025
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGenix Technologies Breakthrough in Real-Time 24/7 Remote Ocular Monitoring
February 20, 2025
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy
February 22, 2024
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
December 26, 2023
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board
December 21, 2023
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors
December 04, 2023
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
December 01, 2023
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGeniX Technologies Inc. Appoints Stephen Tannenbaum to the Company's Business Advisory Board
November 28, 2023
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
November 09, 2023
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device
November 08, 2023
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
October 30, 2023
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGeniX Technologies Inc. Focuses on Prevention of Blindness and Early Detection of Multiple Systemic Diseases
September 18, 2023
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS
August 28, 2023
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGeniX Technologies Inc. Granted Patent for Patient Home Monitoring and Physician Alert System for Ocular Anatomy
July 28, 2023
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGeniX Technologies, Inc. Nears Completion of Institutional Review Board for Research on DNA/GPS Program
June 26, 2023
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPS
June 07, 2023
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
RetinalGeniX Technologies, Inc. to Present at the Emerging Growth Conference Wednesday, October 26, 2022
October 24, 2022
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire
News headline image
Vinay Mehindru, MD, MBA Appointed to RetinalGenix Technologies Inc. Board of Directors
July 26, 2022
From RetinalGeniX Technologies, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is RTGN publicly traded?
Yes, RTGN is publicly traded.
What exchange does RTGN trade on?
RTGN trades on the OTC Traded
What is the ticker symbol for RTGN?
The ticker symbol for RTGN is RTGN on the OTC Traded
What is the current price of RTGN?
The current price of RTGN is 3.990
When was RTGN last traded?
The last trade of RTGN was at 09/16/26 03:45 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap